Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

NIH - National Institutes of Health National Cancer Institute Division of Cancer Treatment and Diagnosis Center for Cancer Research
NCI Experimental Therapeutics Program (NExT)
Contact NExT
Show menu
Search this site
Last Updated: 09/15/14

Phase 0

The NCI established the Developmental Therapeutics Section (DTS) within the CCR so that DCTD could use Phase 0 clinical trial designs as permitted by the FDA’s Exploratory IND Guidance to evaluate agents early in the clinical development process. DTS also designs and conducts Phase I and II trials of novel agents; many of the trials are multicenter collaborations with other specialist cancer centers, oncology groups, and consortia. The potential for rapid patient accrual combined with the world-class resources of the CCR allow the optimum evaluation of promising new anticancer agents.